ABSTRACT
Objective To study the effect of BCG polysaccharide nucleic acid combined with Tripterygium wilfordii polyglycoside(TWP) on inflammatory factors and T cell subsets in patients with chronic urticaria. Methods From January 2015 to January 2017,84 patients of chronic urticaria in Gujiao Central Hospital were selected in the research. The patients were randomly divided into observation group and control group,with 42 cases in each group. The control group was treated with conventional therapy,and the observation group was treated with BCG polysaccharide nucleic acid combined with TWP. The levels of IL－2,IL－4,IL－10,peripheral blood interferon－γ(IFN－γ),T cell subsets ( CD+4, CD+8, CD+4/CD+8) were observed, and the clinical efficacy was compared. Results After treatment,the total effective rate of the observation group was higher than that of the control group[41(97. 62% ) vs. 36(85. 71% )](χ2=3. 896,P＜0. 05). The levels of IL－2 and IFN－γ in the observation group were higher than thoseinthecontrolgroup[(314.54±45.47)ng/Lvs.(285.04±46.84)ng/L,(310.25±32.80)ng/Lvs.(265.14± 28. 11)ng/L](t=2. 928,6. 767,all P＜0. 05). The levels of IL－4 and IL－10 in the observation group were lower thanthoseinthecontrolgroup[(18.65±3.14)ng/Lvs.(26.09±4.52)ng/L,(57.65±6.34)ng/Lvs.(63.74± 6. 82)ng/L](t=8. 760,4. 238,all P＜0. 05). The levels of CD+4,CD+4/CD+8in the observation group were higher thanthoseinthecontrolgroup[(39.86±6.96)% vs.(34.44±7.06)%,(1.60±0.14) vs.(1.34±0.15)](t=3. 543,8. 212,all P＜0. 05). The level of CD+8in the observation group was lower than that in the control group [(24.34±3.99)% vs.(27.24±4.33)%](t=3.191,P＜0.05).Conclusion BCG polysaccharide nucleic acid combined with TWP in the treatment of chronic urticaria can effectively increase peripheral blood IFN－γ and IL－2 levels,decrease IL－4,IL－10 levels,improve levels of inflammatory cytokines and T cell subsets( CD+4,CD+8and CD+4/CD+8),the efficacy is safe and reliable,it is worthy of application and promotion.
ABSTRACT
Objective To explore the application of BCG polysaccharide nucleic acid injection in the treatment of skin diseases.Methods Selected in June 2015 to August 2016 period, in our hospital for skin disease treatment of 200 patients. According to the type of skin disease is divided into chronic eczema, chronic urticaria, alopecia areata and flat warts four groups, each group contains 50 patients. And then each group of patients were randomly divided into two groups, one group as a control group, a group as the observation group, each group of 25 cases. The control group was treated with traditional drug therapy, and the observation group needed to increase the use of BCG polysaccharide nucleic acid injection. The treatment period is for three months. To observe and compare the treatment effect of the control group and the experimental group after three months, that is, to observe and compare patients with chronic eczema, chronic urticaria, alopecia areata and flat warts of the four different types of skin diseases after three months of treatment effect. Results In the patients with chronic eczema, the effective rate of treatment was 96.0％ in the observation group and 68.0％ in the control group. The effective rate of the treatment group was significantly higher than that of the control group (P<0.05). The effective rate was 88.0％ in the observation group and 60.0％ in the control group. The effective rate of the treatment group was significantly higher than that of the control group (P<0.05). In the patients with alopecia areata, The effective rate of treatment was 84.0％ in the observation group and 72.0％ in the control group. The effective rate of the treatment group was significantly higher than that of the control group (P<0.05). In the patients with flat warts, The effective rate was 92.0％ and the effective rate was 68.0％ in the control group. The effective rate of the treatment group was significantly higher than that of the control group (P<0.05). In the different types of skin diseases, the effective rate of treatment was obvious Higher than the control group, the treatment effect was significantly better than the control group (P<0.05). Conclusion For patients with skin diseases using BCG polysaccharide nucleic acid injection for treatment, compared to the traditional drug treatment better. For the different types of skin diseases, the use of BCG polysaccharide nucleic acid injection for treatment can get the best therapeutic effect, so BCG polysaccharide nucleic acid injection in different types of skin disease clinical treatment is a worthy of use and Its promotion of the treatment.
ABSTRACT
Objective To evaluate the clinical efficacy of acupoint injection with BCG-polysaccharide nucleic acid (BCG-PSN) in treating bronchial asthma. Method Seventy-two patients with bronchial asthma were randomized into an acupoint injection group and a muscular injection group, 36 cases in each group. The acupoint injection group was intervened by acupoint injection with BCG-PSN to Zusanli (ST36) and Dingchuan (EX-B1) alternately, 1 mL for two points in total each time; the muscular injection group was intervened by muscular injection at the same dose and frequency, twice a week, for successive 3 months. The pulmonary function and asthma control test (ACT) were estimated before and after intervention and during March of the next year. Result After intervention, the FEV1 values were (80.97±2.31)% and (80.78±2.56)% respectively in the acupoint injection group and muscular injection group, and PEF values were (6.50±0.21)L/s and (6.48±0.25)L/s, and the between-group differences were statistically insignificant (P>0.05). The ACT score was (23.02±1.03) in the acupoint injection group, significantly better than (22.40±2.04) in the muscular injection group (P<0.05). The follow-up study showed that the ACT score in the acupoint injection group was superior to that in the muscular injection group (P<0.05). Conclusion Acupoint injection and muscular injection with BCG-PSN can equally improve the pulmonary function in bronchial asthma, while the acupoint injection can produce a more significant effect than muscular injection in improving ACT.
ABSTRACT
Objective:To study the clinical efficacy and safety of BCG-polysaccharide nucleic acid combined with isotretinoin soft capsules in the treatment of plane warts. Methods:Seventy patients with plane warts were randomly divided into the observation group and the control group(n=35). The control group were treated with isotretinoin soft capsules, limp 10mg, bid, 4 weeks to 10mg, qd. The observation group were given BCG-polysaccharide nucleic acid 1ml, im, every otherday, on the basis of the contrl group. After 8 weeks of treatment, T cell populations and immunoglobulin levels were detected, and the efficacy and adverse reactions were recorded. Results:After the treatment, T cell population level, IgG and IgA of the two groups were significantly improved(P0. 05). Conclusion:The clinical efficacy of BCG-polysaccharide nucleic acid combined with isotretinoin soft capsules in the treatment of plane warts is sig-nificant with promising security.
ABSTRACT
OBJECTIVE@#To explore the effect of bacilli Galmette-Gurin (BCG)-polysaccharide nuceic acid on atopic dermatitis in mice and its mechanism.@*METHOD@#Forty NC/Nga mice were selected and randomly divided into Group A (model group), Group B (dexamethasone treatment group), Group C (BCG polysaccharide nucleic acid treatment group) and Group D (control group) with 10 mice in each group. Atopic dermatitis model were constructed by applying 2, 4-dinitrochlorobenzene on the skin of the mice. Mice in Group D were treated with acetone solution (100 μL) on the foot pad and abdomen after hair removal at the age of 7 weeks, then on ear skin at the age of 8-13 weeks. For mice in A, B and C groups, 100 μL of acetone solution containing 2, 4-dinitrochlorobenzene was applied to the foot pad and the abdomen at the age of 7 weeks, then on ear skins at the age of 8 to 13 weeks. At the age of 7-13 weeks, mice in Group A and Group D were treated with 100 μL saline (i.p.); mice were given dexamethasone (0.1 mL/kg, i.p.) every other day for 7 weeks in Group B; mice were treated with BCG polysaccharide nucleic acid (0.5 mg/kg, i.p.) every other day for 7 weeks in Group C. The ear thickness was measured every week and the scratching frequency was recorded 1 times for 10 min a week. The mice were sacrificed after the last administration of drugs. IgE, IL-4, IL-10, IL-12 and IFN-γ in the plasma were detected using ELISA, and RT-PCR method was employed to detect the concentrations of IL-4, IL-10, IL-12 and IFN-γ proteins. After HE staining, the lesion degree of inflammation in ear tissue was observed microscopically.@*RESULTS@#The ear thickness and scratching frequency of Group A were significantly higher than those in group B, C and D (P0.05); the concentrations of IgE, IL-4 and IL-10 in the plasma and the expression of IL-4, IL-10 mRNA in the spleen tissues of Group A, B and C were all significantly higher than those of Group D (P<0.05); the concentrations of plasma IL-12 and IFN-γ, and spleen protein expression of IL-12 and IFN-γ in Group C mice were significantly higher than those of Group A (P<0.05). Histological observation showed obvious ear tissue exudation, erythema, swelling, desquamation of skin, and scabbing in Group A. Histopathology of the skin lesion also showed hyperkeratosis, focal-parakeratosis, stratum spinosum hypertrophy, mild sponge-like edema, a large number of lymphocytes along with plasma cell infiltration in dermis, angiectasis and hyperemia in Group A, while degree of ear skin lesion in Group B and D mice was significantly lighter than that of Group A.@*CONCLUSIONS@#BCG polysaccharide nucleic acid can significantly reduce the serum IgE concentrations, increase the expression of IL-12, IFN-γ protein, correct the imbalance of Thl/Th2 in atopic dermatitis mice, and has obvious inhibitory effect on atopic dermatitis in NC/Nga mice.
ABSTRACT
Objective: To explore the effect of bacilli Galmette-Gurin (BCG)-polysaccharide nuceic acid on atopic dermatitis in mice and its mechanism. Method: Forty NC/Nga mice were selected and randomly divided into Group A (model group), Group B (dexamethasone treatment group), Group C (BCG polysaccharide nucleic acid treatment group) and Group D (control group) with 10 mice in each group. Atopic dermatitis model were constructed by applying 2, 4-dinitrochlorobenzene on the skin of the mice. Mice in Group D were treated with acetone solution (100 μL) on the foot pad and abdomen after hair removal at the age of 7 weeks, then on ear skin at the age of 8-13 weeks. For mice in A, B and C groups, 100 μL of acetone solution containing 2, 4-dinitrochlorobenzene was applied to the foot pad and the abdomen at the age of 7 weeks, then on ear skins at the age of 8 to 13 weeks. At the age of 7-13 weeks, mice in Group A and Group D were treated with 100 μL saline (. i.p.); mice were given dexamethasone (0.1 mL/kg, i.p.) every other day for 7 weeks in Group B; mice were treated with BCG polysaccharide nucleic acid (0.5 mg/kg, i.p.) every other day for 7 weeks in Group C. The ear thickness was measured every week and the scratching frequency was recorded 1 times for 10 min a week. The mice were sacrificed after the last administration of drugs. IgE, IL-4, IL-10, IL-12 and IFN-γ in the plasma were detected using ELISA, and RT-PCR method was employed to detect the concentrations of IL-4, IL-10, IL-12 and IFN-γ proteins. After HE staining, the lesion degree of inflammation in ear tissue was observed microscopically. Results: The ear thickness and scratching frequency of Group A were significantly higher than those in group B, C and D (. P0.05); the concentrations of IgE, IL-4 and IL-10 in the plasma and the expression of IL-4, IL-10 mRNA in the spleen tissues of Group A, B and C were all significantly higher than those of Group D (. P<0.05); the concentrations of plasma IL-12 and IFN-γ, and spleen protein expression of IL-12 and IFN-γ in Group C mice were significantly higher than those of Group A (. P<0.05). Histological observation showed obvious ear tissue exudation, erythema, swelling, desquamation of skin, and scabbing in Group A. Histopathology of the skin lesion also showed hyperkeratosis, focal-parakeratosis, stratum spinosum hypertrophy, mild sponge-like edema, a large number of lymphocytes along with plasma cell infiltration in dermis, angiectasis and hyperemia in Group A, while degree of ear skin lesion in Group B and D mice was significantly lighter than that of Group A. Conclusions: BCG polysaccharide nucleic acid can significantly reduce the serum IgE concentrations, increase the expression of IL-12, IFN-γ protein, correct the imbalance of Thl/Th2 in atopic dermatitis mice, and has obvious inhibitory effect on atopic dermatitis in NC/Nga mice.
ABSTRACT
Objective To explore the effect of BCG-polysaccharide nucleic acid(BCG-PSN) on the numbers of Th3,Th2 and Th1 cells in peripheral blood mononuclear cell(PBMC) and airway inflammation status in patients with asthma.Methods Twenty-six patients with moderate persistent asthma were enrolled into the study and randomly divided into simple medication group(n=13,accepted Fluticasone/salmeterol alone) and combined medication group(n=13,accepted Fluticasone/salmeterol+BCG-PSN together).The numbers of Th3,Th1 and Th2 cells in PBMC, the serum levels of TGF-β,IFN-γ,IL-4 and IgE and the clinical effect and airway inflammation status were observed at three time points: before,1.5 months after and 3 months after treatment. Results (1)At 1.5 months after treatment,the Th1/Th2 number was significantly higher in the combined medication group than the simple medication group(1.20±0.57 vs 0.79±0.39,t= 2.129,P＜0.05),and the asthma control test scale(ACT) showed similar difference(18.31±1.75 vs.15.54±2.40,t=3.359,P＜0.01) between the two groups.(2)At 3 months after treatment,the Th1/Th2 number was significantly higher in the combined medication group than the simple medication group(1.73±0.74 vs1.16±0.48,t=2.327,P＜0.05),and the ACT also showed the same kind of difference(22.46±1.13 vs.20.23±2.59,t=2.851,P＜0.01) between the two groups.In addition,at this time point the PEF variability was significant lower in the combined medication group than the simple medication group([9.88±2.18]% vs.[12.05±2.74]%,t=2.235,P＜0.05).(3)We found no significant differences in the comparisons of the numbers of T helper cell subsets in PBMC ,the serum levels of cytokines and IgE,the numbers of inflammatory cells in induced sputum between the two groups(Ps＞0.05).(4)No correlation were found between Th3 cell numbers in PBMC and the serum levels of IgE in the two groups.Conclusion The combined use of Fluticasone/salmeterol and BCG-PSN can further correct the imbalance of Th1/Th2 cells,alleviate clinical symptom of asthma and airway hyper-responsiveness.The therapeutic efficacy improves along with the therapy period,better in the combined medication group than the simple medication group.BCG-PSN has no significant effects on the numbers of Th3 in PBMC in patients with asthma.
ABSTRACT
Objective To assess the changes in frequency of peripheral T lymphocytes expressing different cytokines in patients with atopic dermatitis (AD) before and after treatment with BCG-PSN and their relationship with disease severity. Methods A randomized, double blinded and placebo cross-over control study was conducted. A total of 8 patients with AD were recruited in this study. Intramuscular BCG-PSN or placebo was given to patients every other day for 36 days. Flow cytometry was performed to measure the frequency of IL4-, IL5-, IFN-γ- and TNFα-expressing peripheral CD4+ T cells and CD8+ T cells before and after the therapy. Disease severity was evaluated by atopic dermatitis area and severity index score (ADASIS). Results The difference value in IFN-γ+CD8+ T cell frequency before and after therapy was significantly higher in patients treated with BCG-PSN than in those with placebo (8.056 ± 13.962 vs -6.549 ± 10.491, U = 2.26, P< 0.05). There was no statistical difference in the frequency of IL4-, IL5-, TNFa-expressing CD8+ T cells between BCG-PSN- and placebo-treated patients (all P > 0.05). The decrease in ADASIS was 1.56 ± 1.49 in patients treated with BCG-PSN, which was statistically higher than that in placebo-treated patients (-0.05 ± 1.54, U = 2.00, P< 0.05). Conclusion As an immunomodulator, BCG-PSN may control AD by restoring the balance of T-cell subsets.
ABSTRACT
Objective: To study the effect of intracavitary infusion of Huachansu injection combined with polysaccharide nucleic acid fraction of Bacillus Calmette Guérin (BCG-PSN) or cisplatin in the treatment of the malignant pleural and peritoneal effusions. Methods: Seventy patients were randomly divided into two groups. Patients in the treatment group (n = 35) were intracavitarily infused with 20 mL of Huachansu injection and 18 mL of BCG-PSN; patients in the control group (n = 35) were intracavitarily infused with 20 mL of Huachansu injection and 60 mg of cisplatin once a week and the treatment lasted for 2-4 weeks. Results: For the treatment group, the response rate (complete response + partial response) was 83.3% in 24 cases with malignant pleural effusion and 63.6% in 11 cases with malignant peritoneal effusion. The total response rate was 77.1% (27/35) in the treatment group. The KPS score was elevated in 26 cases, stable in 7 cases, and decreased in 2 cases. For the control group, the response rate (complete response + partial response) was 86.4% in 22 cases with malignant pleural effusion and 69.2% in 13 cases with malignant peritoneal effusion. The total response rate was 80.0% (28/35). The KPS score was increased in 16 cases, stable in 11 cases, and decreased in 8 cases. There was no significant difference in clinical efficacy between the two groups (P > 0.05). Patients in the treatment group had less adverse reaction and a more improved living quality than those in the control group (P < 0.05). Conclusion: Intracavitary infusion of Huachansu injection combined with BCG-PSN or cisplatin was effective in the treatment of malignant pleural and peritoneal effusions, but Huachansu injection plus BCG-PSN had less toxicity especially for the advanced patients who can not tolerate the intracavitary chemotherapy.
ABSTRACT
Objective To evaluate the preventive effect of BCG-PSN on respiratory infection of patients with chronic obstructive pulmonary disease.Methods 48 cases with COPD were randomly divided into two groups:the BCG-PSN group and the control group.The BCG-PSN group received BCG-PSN,0 5mg,im,twice a week for 18 times injection in addition to the routine therapy,and the control group only received routine therapy.Both groups were followed up every two weeks for six months.The serum IgA,IgG,IgM levels were determined before and 4,24 weeks after the treatment.Results Cases of infection and their lasting days,infective rate in the BCG-PSN group were significantly lower than that of the control group(P